M. Reding

R. John, M. Reding, Cindy M. Martin, 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Response of complex immune‐mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia

R. Bollag, N. Key, M. Reding, 2012, European journal of haematology.

Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders

L. Valentino, M. Recht, R. Butler, 2021, Journal of blood medicine.

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

E. Santagostino, M. Mancuso, I. Pabinger, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Effect of late prophylaxis in hemophilia on joint status: a randomized trial

C. Peterfy, C. Kempton, D. Raunig, 2017, Journal of thrombosis and haemostasis : JTH.

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

B. Kerlin, C. Négrier, M. Mancuso, 2020, Thrombosis and Haemostasis.

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.

E. Santagostino, H. Ng, S. Lalezari, 2019, Thrombosis research.

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors

J. Luck, A. al‐Sabbagh, C. Hermans, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

C. Négrier, P. Holme, I. Pabinger, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature

C. Königs, A. Iorio, M. Mancuso, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Randomized, Controlled, Parallel-Group Trial of Routine Prophylaxis Versus On-Demand Treatment With rFVIII-FS in Adults With Severe Hemophilia A (SPINART).

C. Kempton, T. Lissitchkov, M. Manco‐Johnson, 2013 .

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

S. Meeks, G. Batsuli, M. Callaghan, 2018, Blood.

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

C. Négrier, P. Holme, M. Mancuso, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

E. Santagostino, H. Ng, S. Lalezari, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

E. Santagostino, S. Lalezari, M. Reding, 2019, Blood.

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

I. Pabinger, S. Lalezari, M. Reding, 2018, Blood.

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

P. Holme, M. Reding, L. Hvitfeldt Poulsen, 2018, Blood.

Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A

J. Oldenburg, G. Castaman, T. Matsushita, 2021, BMJ Open.

CD4+ T cells specific for factor VIII as a target for specific suppression of inhibitor production.

N. Key, H. Wu, M. Reding, 2001, Advances in experimental medicine and biology.

Is prophylaxis required for delivery in women with factor VII deficiency?

M. Reding, L. Baumann Kreuziger, C. Morton, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Mechanism of the Immune Response to Human Factor VIII in Murine Hemophilia A

H. Wu, P. Lollar, E. Parker, 2001, Thrombosis and Haemostasis.

Unmet needs in the transition to adulthood: 18‐ to 30‐year‐old people with hemophilia

D. Cooper, N. Iyer, M. Witkop, 2015, American journal of hematology.

Opioid exposure in haemophilia patients is common and underreported

M. Reding, R. Freese, S. Kearney, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: a critical review from the physician's perspective.

J. Astermark, C. Hermans, R. Klamroth, 2022, Critical reviews in oncology/hematology.

Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.

N. Uriel, S. Adatya, P. Eckman, 2015, JACC. Heart failure.

Sensitization of CD4+ T Cells to Coagulation Factor VIII: Response in Congenital and Acquired Hemophilia Patients and in Healthy Subjects

N. Key, H. Wu, M. Reding, 2000, Thrombosis and Haemostasis.

Patient‐ and caregiver‐reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE)

L. Valentino, D. Cooper, G. Young, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report

C. Tignanelli, M. Reding, J. Harmon, 2023, Clinical case reports.

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia

C. Thornburg, J. Boice, D. Quon, 2023, Expert review of hematology.

G. Vercellotti, M. Arora, V. Bachanova, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study (Preprint)

Deborah L. Pestka, G. Melton, N. Shippee, 2021 .

Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study

Deborah L. Pestka, G. Melton, N. Shippee, 2021, JMIR medical informatics.

Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies

A. Ashrani, D. Grill, M. Reding, 2022, American Journal of Hematology.

Liver Transplantation for High Output Heart Failure Secondary to HHT: A Case Report and Review of the Literature

Saleh Elwir, J. Lake, S. Chinnakotla, 2015 .

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

C. Hermans, G. Di Minno, P. Holme, 2023, Therapeutic advances in hematology.

Use of recombinant human antithrombin concentrate in pregnancy

M. Reding, L. B. Kreuziger, T. Prosen, 2013, International Journal of Women's Health.

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.

J. Oldenburg, M. Ozelo, D. Quon, 2023, The New England journal of medicine.

Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival

M. Reding, D. Weisdorf, M. Reding, 2015, Bone Marrow Transplantation.

Hematologic Problems in the Surgical Patient

N. Key, M. Reding, J. Weitz, 2017 .

Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

C. Kempton, T. Lissitchkov, M. Manco‐Johnson, 2013, Journal of thrombosis and haemostasis : JTH.

Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII

I. Pabinger, H. Ng, M. Reding, 2017, Journal of thrombosis and haemostasis : JTH.

Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease

R. Watts, E. Kraut, B. Kerlin, 2009, Haemophilia.

Efficacy and safety of a VWF/FVIII concentrate (wilate®) in inherited von Willebrand disease patients undergoing surgical procedures

C. Kessler, T. Lissitchkov, A. Srivastava, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors

M. Reding, A. Hurlet, K. Stine, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

J. Astermark, J. Oldenburg, C. Leissinger, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Patient‐ and caregiver‐reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE)

L. Valentino, D. Cooper, G. Young, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.